R
Ralph J. DeBerardinis
Researcher at University of Texas Southwestern Medical Center
Publications - 325
Citations - 55892
Ralph J. DeBerardinis is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 88, co-authored 271 publications receiving 42314 citations. Previous affiliations of Ralph J. DeBerardinis include University of Texas at Dallas & Children's Medical Research Institute.
Papers
More filters
Journal ArticleDOI
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone
Gaurab Chakrabarti,Molly A. Silvers,Mariya Ilcheva,Yuliang Liu,Zachary R. Moore,Xiuquan Luo,Jinming Gao,Glenda G. Anderson,Lili Liu,Venetia R. Sarode,David E. Gerber,Sandeep Burma,Ralph J. DeBerardinis,Stanton L. Gerson,David A. Boothman +14 more
TL;DR: A treatment strategy is presented that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.
Journal ArticleDOI
Mutations in mitochondrial enzyme GPT2 cause metabolic dysfunction and neurological disease with developmental and progressive features
Qing Ouyang,Tojo Nakayama,Ozan Baytas,Shawn M. Davidson,Chendong Yang,Michael Schmidt,Sofia B. Lizarraga,Sasmita Mishra,Malak Ei-Quessny,Saima Niaz,Mirrat Gul Butt,Syed Imran Murtaza,Afzal Javed,Haroon Rashid Chaudhry,Dylan J. Vaughan,R. Sean Hill,Jennifer N. Partlow,Seung Yun Yoo,Anh Thu N. Lam,Ramzi Nasir,Muna Al-Saffar,A. James Barkovich,Matthew Schwede,Shailender Nagpal,Anna Rajab,Ralph J. DeBerardinis,David E. Housman,Ganeshwaran H. Mochida,Eric M. Morrow +28 more
TL;DR: An important role is revealed for the GPT2 enzyme in mitochondrial metabolism with relevance to developmental as well as potentially to neurodegenerative mechanisms in large kindreds initially ascertained for intellectual and developmental disability.
Journal ArticleDOI
Metabolic plasticity maintains proliferation in pyruvate dehydrogenase deficient cells
Kartik N. Rajagopalan,Robert A. Egnatchik,Maria A. Calvaruso,Ajla T. Wasti,Mahesh S. Padanad,Lindsey K. Boroughs,Bookyung Ko,Christopher T. Hensley,Melih Acar,Zeping Hu,Lei Jiang,Juan M. Pascual,Pier Paolo Scaglioni,Ralph J. DeBerardinis +13 more
TL;DR: The findings reveal that this central enzyme is essentially dispensable for growth and proliferation of both primary cells and established cell lines, and indicates that rapid cell proliferation occurs independently of PDH activity.
Journal ArticleDOI
Biomarker accessible and chemically addressable mechanistic subtypes of braf melanoma
Banu Eskiocak,Elizabeth A. McMillan,Saurabh Mendiratta,Rahul K. Kollipara,Hailei Zhang,Caroline G. Humphries,Chang-Guang Wang,Jose Garcia-Rodriguez,Ming Ding,Aubhishek Zaman,Tracy I. Rosales,Ugur Eskiocak,Michael P. Smith,Jessica Sudderth,Kakajan Komurov,Ralph J. DeBerardinis,Claudia Wellbrock,Michael A. Davies,Jennifer A. Wargo,Yonghao Yu,Jef K. De Brabander,Noelle S. Williams,Lynda Chin,Helen Rizos,Georgina V. Long,Ralf Kittler,Michael A. White +26 more
TL;DR: This study identified two mechanistic subtypes of BRAFV600 melanoma that inform new cancer cell biology and offer new therapeutic opportunities and identified robust biomarkers that can detect these subtypes in patient samples and predict clinical outcome.
Journal ArticleDOI
Metabolic diversity in human non-small cell lung cancer
Pei-Hsuan Chen,Ling Cai,Hyun Seok Kim,Rebecca Britt,Guanghua Xiao,Michael A. White,John D. Minna,Ralph J. DeBerardinis +7 more
TL;DR: A well-characterized panel of lung cancer cell lines is used to develop the most comprehensive view of cancer cell metabolism to date, and metabolic phenotyping could produce actionable biomarkers to optimize therapy.